Member Info for EmeraldCarrots

Wow. Don't see that very often!

Bantham. That statement is ridiculous. For example. Angle are looking for a Pharma partner to join them and Bioview to market the HER2 system Bioview and Angle have spent just over a year developing. An up front payment to become that partner could be in the milions. Just one example. We know they talk to Eisai and Astrazeneca already......

You are so quick to look on the bad side!

All IMHO.

Landing a half million £ contract with Astrazeneca might be better appreciated by the yanks!

Bantham.

It's 4th May 2024. Angle cash runway WAS until 1st quarter 2025. It is possible a cash raise won't be necessary. Mr Newland in the interview said they are talking to "11 other possible customers, 6 are "household" names"..........

Bound to be additional contracts from Eisai and Astrazeneca too IMHO.........

8 months to land more contracts. It's easily doable now.

All IMHO.

After the FIRST Astrazeneca contract on 24th April.....

THIS TIME I THINK 20P PLUS.

USA interest..........

aLL imho!!!

Will top 20p a share TODAY IMHO!!!!!!!!!!!!! Listen to this!!!!:-

https://www.proactiveinvestors.co.uk/companies/news/1046802/angle-announces-second-assay-with-astrazeneca-as-it-deepens-relationship-with-pharma-giant-1046802.html

holy *****!!!!

"astra have 460 active cance trials with 140,000 patients involved.".

halo effect.... knock on impact. pipeline of 11 other possible customers, 6 are "household" names!!!!!!!>>

https://www.proactiveinvestors.co.uk/companies/news/1046802/angle-announces-second-assay-with-astrazeneca-as-it-deepens-relationship-with-pharma-giant-1046802.html

Parsortix has FDA approval for medical use in the USA for Breast cancer. There is a massive world wide market for this alone. Massive.

Even more massive IMHO it can be used for ***ANY cancer during a cancer drug trial***. There is £ millions to be made from Parsortix being used during drug trials. The RNS of 4th Jan IS THE MOST SIGNIFICANT ANNOUNEMENT AGL HAVE MADE EVER IMHO. It shows with the dual CtDNA and CTC analysis a cancer that has matastacised can be MONITORED to find out HOW THE NEW DRUG IS PERFORMING !!!!!!!!! Before. DURING and AFTER treatment!!!!

https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html

All IMHO.

Sp peaked around 13:45 @ 17p bid After the FIRST Astrazeneca contract on 24th April.....

Hello.

Ask 16p now.

After the FIRST Astrazeneca contract on 24th April.....

USA interest presumably..........

Angle now have one contract with Eisai Inc. of Japan (top 100 Company in Japan) and two contracts with Astrazeneca (Top 100 UK Plc). Doing business with these MASSIVE Companies is only going to lead to more and more contracts with them.......... AND other Plc's IN THE WORLD. The World is a big place and there are thousands of other Companies out that can obviously contact Angle via their WEB site and go from there. The "Combined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample" is going to be transformational for Angle, and they have not YET announced the first customer following the RNS of 4th Jan:-

https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html

Can't wait!! They are going to be turning customers away IMHO.

All IMHO.

IMHO all, and I mean ALL Companies that AGL now work with will **ALSO** want this "Combined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample" for cancer treatment studies that involve metastasized cancer. It is obvious. They *******MUST******* WANT THIS imho. HOW ELSE CAN THEY MONITOR THE CANCER????

"BREAKTHROUGH CLINICAL RESULTS PROVIDE A UNIQUE INSIGHT INTO THE PROGRESSION OF EACH PATIENT'S CANCER.

Combined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample highlights potential for the Parsortix system to identify key variants (DNA mutations) missed by other approaches to help guide treatment decisions

The new DNA sample-to-answer molecular solution combining CTC and ctDNA analysis is expected to be a driver of product and pharma services sales".

https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html

These agreements to date are just the start.

Angle simply must be in discussions about the "Combined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample". It will me massive IMHO..............

All IMHO.

Up 20% now.

See here:-

https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-large-pharma-gvzk9wgh1la0ljx.html

Https://www.washingtonpost.com/world/2024/05/02/israel-hamas-war-news-gaza-palestine/

Mesquida.

"Surely 37p was the top ofbthe January spoke ?2

======================================

Sorry. My memory said 51p but checking the chart it was arounf 31p! Still over two fold the currect sp of course.

One would have thought. We will see. Like the odds and potential 100% plus profit myself!

All IMHO.

Nudgesta.

"The sp has never been that low??"

======================

Results due this month.

Lowest I remember was about 9.8p Nov 2023. Highest since then 51p ish (spike up due to RNS of 4th Jan 2024 - Cancer breakthrough). Recently spiked to 17p (contract with Astrazeneca). Illiquid share means it moves a lot on low volume (either way). Thus a good news RNS often spikes the sp up a lot.......

Currently 14p.

All IMHO.